Company / Revenue
Zenas BioPharma, Inc. Revenue History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$10.0M
FY2025
5-year range
$10.0M / $50.0M
FY2023-FY2025
Trend
-80.0%
vs FY2024
Sector context
#135 of 155
Health Care
What the data says
Zenas BioPharma, Inc.'s revenue of $10M is lower than 87% of companies in the Health Care sector (FY2025). Declined from $50M to $10M over the past 2 years.
Based on SEC 10-K filings.
$10M in FY2025.
Declined from $50M to $10M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 155This company $10.0M Sector average $4.5B
▼
-99.8% below sector average
Key checks
Key Insights
- In FY2025, revenue decreased 80.0% year-over-year.
- Ranks #135 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.0M | -80.0% |
| FY2024 | $50.0M | +0.0% |
| FY2023 | $50.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026